SI-053
Glioblastoma (Brain Cancer)
Pre-clinicalActive
Key Facts
About Double Bond Pharmaceutical
Double Bond Pharmaceutical is a private, preclinical-stage biotech company leveraging its proprietary BeloGal® drug delivery platform to enhance the efficacy and safety of existing medicines. The company's strategy centers on reformulating proven drugs for targeted local or organ-specific delivery, with lead programs in oncology and infectious diseases. Based in Uppsala, Sweden, DBP aims to address significant unmet needs in glioblastoma, liver cancer, and pneumonia by improving therapeutic profiles and reducing systemic toxicity.
View full company profileTherapeutic Areas
Other Glioblastoma (Brain Cancer) Drugs
| Drug | Company | Phase |
|---|---|---|
| TVI-Brain-1 | TVAX Biomedical | Phase 2b |